0001209191-22-020611.txt : 20220322 0001209191-22-020611.hdr.sgml : 20220322 20220322184418 ACCESSION NUMBER: 0001209191-22-020611 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220318 FILED AS OF DATE: 20220322 DATE AS OF CHANGE: 20220322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Campbell Bradley L CENTRAL INDEX KEY: 0001400971 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 22761094 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-18 0 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001400971 Campbell Bradley L C/O AMICUS THERAPEUTICS, INC. 3675 MARKET STREET PHILADELPHIA PA 19104 1 1 0 0 Chief Operating Officer Common Stock 2022-03-18 4 M 0 10940 3.53 A 595955 D Common Stock 2022-03-18 4 S 0 10940 10.0024 D 585015 D Stock Options (right to buy) 3.53 2022-03-18 4 M 0 10940 0.00 D 2023-01-28 Common Stock 10940 49245 D The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.00 to $10.02 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of the transaction date. /s/ Christian Formica, Attorney-in-Fact 2022-03-22